Lixisenatide for type 2 diabetes mellitus

被引：74

作者：

Christensen, Mikkel ^{[1
]}

Knop, Filip K. ^{[1
]}

Vilsboll, Tina ^{[1
]}

Holst, Jens J. ^{[2
]}

机构：

[1] Univ Copenhagen, Gentofte Hosp, Diabet Res Div, Dept Internal Med F, DK-2900 Hellerup, Denmark

[2] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen N, Denmark

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 04期

关键词：

AVE0010; GETGOAL; GLP-1; incretin mimetics; lixisenatide; type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; RECEPTOR AGONIST AVE0010; BETA-CELL FUNCTION; INSULIN-SECRETION; DOUBLE-BLIND; OPEN-LABEL; EXENATIDE; HEALTHY; HYPERGLYCEMIA; DYSFUNCTION;

D O I：

10.1517/13543784.2011.562191

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered: Pharmacological, preclinical and clinical evidence demonstrating the applicability of lixisenatide for the treatment of T2DM are reviewed. Available data and pending clinical development are summarized, critically appraised and compared to competitor drugs. The most relevant papers and meeting abstracts published up to November 2010 are used as sources for this review. Expert opinion: Efficacy and safety in T2DM are demonstrated with lixisenatide in monotherapy and in combination with metformin. However, limited data with the intended once-daily 20 mu mu g subcutaneous dosing necessitate further evaluation of lixisenatide as add-on to various antidiabetic treatments. It remains to be established whether the slightly differing chemical properties compared to other GLP-1 receptor agonists including a rather short duration of action will be a disadvantage or maybe even an advantage, for example, when combined with long-acting insulin.

引用

页码：549 / 557

页数：9

共 49 条

[1] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[2]

BECKER RHA, EASD 46 ANN M 20 24

[3] Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].

Buse, John B. ;

Rosenstock, Julio ;

Sesti, Giorgio ;

Schmidt, Wolfgang E. ;

Montanya, Eduard ;

Brett, Jason H. ;

Zychma, Marcin ;

Blonde, Lawrence .

LANCET, 2009, 374 (9683) :39-47

[4] β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].

Butler, AE ;

Janson, J ;

Bonner-Weir, S ;

Ritzel, R ;

Rizza, RA ;

Butler, PC .

DIABETES, 2003, 52 (01) :102-110

[5] Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide? [J].

Christensen, Mikkel ;

Knop, Filip K. .

CURRENT DIABETES REPORTS, 2010, 10 (02) :124-132

[6] BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].

DEACON, CF ;

NAUCK, MA ;

TOFTNIELSEN, M ;

PRIDAL, L ;

WILLMS, B ;

HOLST, JJ .

DIABETES, 1995, 44 (09) :1126-1131

[7] DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].

DEACON, CF ;

JOHNSEN, AH ;

HOLST, JJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957

[8]

Distiller LRP, 2008, 68 ANN M AM DIAB ASS

[9] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].

Drucker, Daniel J. ;

Buse, John B. ;

Taylor, Kristin ;

Kendall, David M. ;

Trautmann, Michael ;

Zhuang, Dangliang ;

Porter, Lisa .

LANCET, 2008, 372 (9645) :1240-1250

[10] The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications [J].

Dunning, Beth Elaine ;

Gerich, John E. .

ENDOCRINE REVIEWS, 2007, 28 (03) :253-283

← 1 2 3 4 5 →